EUVIMEDEUVIMED entdecken
Crossref

Aripiprazole – a collection of handful information for the practitioner

Anna Antosik-Wójcińska

Medycyna Faktów · 2021

DOI: 10.24292/01.mf.0121.12 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medycyna Faktów, 2021. Verfasst von Anna Antosik-Wójcińska.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aripiprazole is an atypical neuroleptic used in schizophrenia and bipolar I disorder. It has low risk of inducing extrapyramidal symptoms and QT prolongation. It has favorable safety profile (including the metabolic one), so it can be used in somatically burdened patients, patients over 65 years of age, and obese patients. The drug in low doses has an activating and antidepressant effect, while in doses exceeding 20 mg/24 h – antipsychotic and anti-manic.

Zitieren

APA

Antosik-Wójcińska, A. (2021). Aripiprazole – a collection of handful information for the practitioner. Medycyna Faktów. https://doi.org/10.24292/01.mf.0121.12

Vancouver

Antosik-Wójcińska A. Aripiprazole – a collection of handful information for the practitioner. Medycyna Faktów. 2021. doi:10.24292/01.mf.0121.12

BibTeX
@article{AntosikWjciska2021,
  author = {Antosik-Wójcińska, Anna},
  title = {Aripiprazole – a collection of handful information for the practitioner},
  journal = {Medycyna Faktów},
  year = {2021},
  doi = {10.24292/01.mf.0121.12}
}
Kostenlos starten →